Response Genetics Inc. announced the availability of new testing capabilities to advance cancer immunotherapy clinical development. The Immuno-Oncology assay, which runs on HTG Molecular's Edge System, is designed to measure the RNA expression of 26 commonly investigated immunotherapy related genes enabling screening for response to immunoregulatory pathways. The Iummo-Oncology test will be made available to all of Response Genetics' existing biopharmaceutical partners, and new potential partners, to aid in development of biomarker driven cancer immunotherapy clinical trials.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2016 | Response Genetics, Inc Bankruptcy Case Dismissed | CI |
2016 | Motion for Case Dismissal Filed for Response Genetics, Inc | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 38 | |
+53.84% | 59.28B | |
+41.42% | 40.94B | |
-5.43% | 40.17B | |
-5.56% | 28.69B | |
+11.92% | 26.63B | |
-20.77% | 18.89B | |
+30.00% | 12.46B | |
+0.64% | 12.42B | |
+26.78% | 12.26B |
- Stock Market
- Equities
- RGDXQ Stock
- News Response Genetics, Inc
- Response Genetics, Inc Launches New Test for Cancer Immunotherapy Drug Development